A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
170 enrolled
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Phase 2 Recruiting
30 enrolled
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Phase 2 Recruiting
54 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
AHEAD-MERIT
Phase 2/3 Recruiting
350 enrolled
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Phase NA Recruiting
40 enrolled
New MRI Biomarkers in Head and Neck Cancers
Recruiting
200 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
WOLF
Phase 2 Recruiting
87 enrolled
FIERCE-HN
Phase 3 Recruiting
410 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
120 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Phase 2 Recruiting
20 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
150 enrolled
GUARDIAN-101
Phase 1 Recruiting
90 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
SLV-154 Treatment of Metastatic Solid Tumors
Phase 1 Recruiting
70 enrolled
TAGNOT
Phase 1/2 Recruiting
58 enrolled
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Phase NA Recruiting
590 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/2 Recruiting
242 enrolled
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 Recruiting
56 enrolled
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Phase 1 Recruiting
36 enrolled
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 Recruiting
12 enrolled
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting
50,000 enrolled
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Phase 1 Recruiting
570 enrolled
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2 Recruiting
208 enrolled
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
76 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 Recruiting
40 enrolled
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/2 Recruiting
80 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
Phase NA Recruiting
30 enrolled
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2 Recruiting
32 enrolled
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase 1/2 Recruiting
160 enrolled
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
51 enrolled
COACH
Phase NA Recruiting
625 enrolled
PembroMetaRT
Phase 3 Recruiting
102 enrolled
AB122 Platform Study
Phase 1 Recruiting
917 enrolled
SUPPRESS
Phase 2 Recruiting
46 enrolled
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Phase 2 Recruiting
48 enrolled
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Phase 3 Recruiting
244 enrolled